Group 1 - The global biotech and pharmaceutical investment and financing activities are expected to rebound significantly in 2025, driven by the robust development of innovative drug technology platforms, leading to a comprehensive recovery in the CXO industry and sustained industry prosperity into 2026 [1] - The Chinese CRO market is projected to return to a growth trajectory in 2025, with a notable 19% year-on-year increase in IND numbers and a substantial rise in BD transaction amounts, indicating a vibrant domestic innovative drug market [1] - The demand side globally is showing a strong rebound, establishing a solid foundation for growth, with biotech financing reaching a historical high in Q4 2025 and multinational pharmaceutical companies experiencing a recovery in demand [1] Group 2 - WuXi AppTec (药明康德) is expected to report impressive performance in 2025, with adjusted net profit increasing by 41.3%, driven by the TIDES business, which has seen revenue growth exceeding 90% [2] - WuXi Biologics has reached a record high of 945 projects, with a 30% growth in dual monoclonal and ADC projects, indicating a strong pipeline for future commercialization [2] - WuXi AppTec's subsidiary, WuXi STA, is focusing on the ADC/XDC sector, with revenue growth exceeding 40% in 2025 and an increase in global market share to over 24% [2] Group 3 - The Chinese clinical CRO market is at a clear turning point, with Tigermed (泰格医药) benefiting from the industry recovery, as order prices stabilize and the domestic clinical pipeline grows alongside improved financing conditions [3] Group 4 - Global CDMO giants are accelerating expansion, with optimistic performance guidance; Fujifilm is expected to secure $8 billion in new orders in 2025, reflecting strong demand for large molecule CDMO services [4] - Charles River anticipates an improvement in order trends starting in H2 2025, with a forecast for revenue growth in its safety assessment business by H2 2026, serving as an early indicator of recovery in the CXO industry [4] Group 5 - Investment recommendations include focusing on leading clinical CRO platforms like Tigermed and niche leaders such as Pruis, as well as front-end CRO companies with shorter order fulfillment cycles and greater marginal elasticity [5] - In the CDMO sector, attention is advised on leading companies in the peptide supply chain, ADC beneficiaries, and those with forward-looking layouts in small nucleic acids, as well as companies with significant potential for marginal traction from large products [5]

Core Viewpoint - Dongning Bio has submitted its application to the Hong Kong Stock Exchange for the third time, showing improved financial performance after previous failures, but faces challenges with high goodwill from aggressive acquisitions [1] Financial Performance - Dongning Bio reported revenues of 814 million yuan, 843 million yuan, and 658 million yuan for the years 2023, 2024, and the first three quarters of 2025, respectively, with net profits of -315 million yuan, -27.5 million yuan, and 14.25 million yuan during the same periods [1] - The company's revenue is primarily derived from two segments: bioprocess solutions and laboratory products and services, with bioprocess solutions accounting for 77%, 75.7%, and 77.1% of total revenue during the reporting period [1] - The growth in overseas revenue has been a key factor in achieving profitability, with overseas business revenues of 69.52 million yuan, 95.3 million yuan, and 112 million yuan, increasing its contribution from 9.8% to 17.1% of total revenue [1] Market Position - The domestic market share of local companies providing bioprocess solutions has increased from 22.6% in 2020 to 36.8% in 2024, with Dongning Bio ranking second among approximately 200 local providers [2] Expansion Strategy - Dongning Bio has emphasized its comprehensive bioprocess solutions covering all major steps from cell revival to purification and filtration, which is closely linked to its aggressive acquisition strategy [3] - Since 2019, the company has acquired nine firms, expanding its business lines to include bioreactors, disposable products, filters, and nano-drug formulation systems [3] - The company announced a controlling acquisition of Kangyuan Technology in May 2025, entering the virus filter consumables market [3] Acquisition Quality Concerns - The quality of acquisition targets is under scrutiny, as Kangyuan Technology, established in 2023 with a registered capital of 3.99 million yuan and only two employees, holds a utility model patent for a small-volume virus filter [4] - The market for virus filters is primarily dominated by imported brands, and the effectiveness of Dongning Bio's strategy to promote domestic solutions remains to be seen [4] Goodwill Challenges - As of September 30, 2025, Dongning Bio's goodwill stood at 843 million yuan, primarily arising from its acquisitions, posing a risk of impairment if future cash flow estimates fall short [5] - The company acknowledges potential difficulties in integrating acquired businesses and achieving expected cost savings, which could adversely affect its operations and financial performance [5] - Revenue from the top five customers accounted for 31.1%, 23.9%, and 32% of total revenue during the reporting period, with WuXi Biologics being the largest customer, contributing 14.9%, 10.9%, and 12.1% of total revenue [5]

SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, jointly announced today the signing of a strategic collaboration agreement on the development and manufacturing of multiple next-generation bi-/multi-functional fusion programs from HanchorBio’s pip ...

Market Overview - The pharmaceutical and biotechnology index declined by 0.39% last week, outperforming the CSI 300 index by 0.23 percentage points but underperforming the ChiNext index by 1.50 percentage points, ranking 27th among 31 sub-industries [4] - The Hong Kong Hang Seng Healthcare Index fell by 2.75%, lagging behind the Hang Seng Index by 2.1 percentage points [4] R&D Progress - Recent clinical application advancements include BNT324 from InnoCare Pharma and HCB101 from Fuhong Hanlin [5] - QX004N from Qianxin Biopharma is in Phase I clinical trials, IBI3002 from Innovent Biologics is in Phase II, and HRS-8080 from Hansoh Pharma is in Phase III [5] Company Insights - WuXi AppTec's companies reported strong performance expectations, indicating robust growth momentum in the CXO sector [6] - WuXi AppTec is projected to achieve revenue of 45.456 billion yuan in 2025, a year-on-year increase of 15.84%, with TIDES business revenue expected to grow over 90% [6] - WuXi Biologics plans to add 209 comprehensive projects in 2025, with two-thirds being bispecific antibodies and ADC drugs, and a total of 99 projects in Phase III and commercialization [6] - WuXi AppTec's subsidiary, WuXi AppTec Co., expects revenue and adjusted net profit to grow over 45% in 2025, with a global market share increase to 24% [6] - The company aims to invest over 7 billion yuan in capacity expansion from 2026 to 2029, targeting a compound annual growth rate of 30%-35% from 2025 to 2030 [6] Investment Strategy - Future investments in the pharmaceutical sector should focus on the intrinsic clinical value logic, addressing clinical needs of patients and doctors [7] - Both domestic medical insurance policies and global expansion strategies are increasingly assigning higher premiums to clinical value [7]

Group 1: Steel Industry - The price of oriented silicon steel has reached the lowest level since 2018, indicating a significant decline in metal cycle products [5] - The high furnace capacity utilization rate in January is expected to be the highest in five years for the same period [5] - The price of titanium dioxide and glass remains low in the real estate completion chain [5] Group 2: Oil and Chemical Industry - IEA has raised the 2026 global oil demand forecast, expecting an increase of 930,000 barrels per day [5] - Geopolitical tensions in Iran and Cuba have led to an increase in oil price risk premium, with Brent and WTI crude oil prices rising by 1.9% and 3.5% respectively [5] Group 3: Electric and Environmental Industry - Space photovoltaic technology has become a market hotspot, with Tesla and SpaceX planning to build a total of 200GW photovoltaic capacity in the U.S. over the next three years [6] - The current market liquidity is abundant, and the commercial aerospace sector is a key focus, with expectations for significant performance in the space photovoltaic sector [6] Group 4: Utilities Industry - The cumulative electricity market transaction volume in 2025 reached 66,394 billion kilowatt-hours, a year-on-year increase of 7.4% [7] - The national electricity load has reached new highs due to cold wave impacts, and policies to enhance green electricity consumption are expected to boost the green electricity sector [7] Group 5: High-end Manufacturing - The export share of emerging markets is expected to increase further in 2025, with North America showing the most significant decline [7] - The export growth rates for electric tools, manual tools, and lawn mowers have varied, with notable increases in specific categories [7] Group 6: Pharmaceutical and Biotechnology - WuXi AppTec's companies have shown strong performance, indicating robust growth momentum in the CXO sector [8] - WuXi Biologics is expected to add 209 comprehensive projects in 2025, with revenue and adjusted net profit growth exceeding 45% for WuXi AppTec [8] Group 7: Food Industry - Li Gao Food has projected a revenue of 4.26-4.42 billion yuan for 2025, reflecting a year-on-year growth of 11.07%-15.24% [8] - The expected net profit for the parent company is between 311-331 million yuan, indicating a growth of 16.06%-23.52% [8]

Core Viewpoint - WuXi Biologics and Hanchor Bio, Inc. have signed a strategic cooperation agreement to jointly advance the development and production of next-generation bispecific and multispecific antibodies [1][7]. Group 1: Strategic Cooperation - The agreement entails WuXi Biologics providing end-to-end integrated services for biopharmaceutical development and production, including cell line development, process and bioassay development, formulation development, and GMP production [2][9]. - The collaboration aims to accelerate clinical translation processes, enhance CMC execution efficiency, and support Hanchor Bio's innovative fusion protein product portfolio based on the Fc-based design biopharmaceutical (FBDB™) platform for global scale development and production [4][12]. Group 2: Company Background - Hanchor Bio, established in December 2020, is a global clinical-stage biotechnology company focused on developing next-generation immunotherapies for oncology and autoimmune diseases [4][12]. - The FBDB™ platform supports the design of multifunctional biopharmaceuticals with diverse targeting mechanisms, aiming to activate both innate and adaptive immune pathways to overcome challenges associated with current anti-PD1/L1 immunotherapies [4][12]. - Hanchor Bio successfully provided proof-of-concept data in multiple in vivo tumor animal models using the FBDB™ platform [4][12]. - In September of the previous year, Hanchor Bio completed a capital increase of 160 million RMB to accelerate the development of multiple new drugs [4][12].

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in their stock prices over the next 12 months [29]. Core Insights - The MSCI China Healthcare Index has increased by 9.2% since the beginning of 2026, outperforming the MSCI China Index, which rose by 5.6% [1]. - The pharmaceutical industry has seen significant growth, driven by strong institutional investor interest and the ongoing trend of innovative drugs going global [1]. - The report emphasizes the importance of clinical progress and data validation for pipelines that have already gone overseas, suggesting that this trend will continue in the long term [1]. Summary by Sections Industry Overview - The report highlights a robust trend in the outbound licensing of innovative drugs, with multiple business development (BD) transactions occurring at the start of 2026, reflecting a high level of activity in the sector [4]. - Key transactions include significant upfront and milestone payments for various drugs, indicating strong market interest and potential for future growth [4]. Company Ratings and Valuations - The report provides detailed valuations for several companies, including: - **Sangfor Technologies (1530 HK)**: Market cap of $7,598.4 million, target price of $37.58, with a 54% upside potential [2]. - **Gusongtang (2273 HK)**: Market cap of $963.3 million, target price of $44.95, with a 46% upside potential [2]. - **WuXi AppTec (2268 HK)**: Market cap of $10,551.0 million, target price of $88.00, with a 28% upside potential [2]. - **China National Pharmaceutical Group (1177 HK)**: Market cap of $15,951.4 million, target price of $9.40, with a 42% upside potential [2]. Market Trends - The report notes that the competition in the PD-(L)1/VEGF space is intensifying, with several companies advancing their clinical trials and aiming for first-line indications [4]. - The report suggests that the efficiency and breadth of clinical trials, as well as the richness of combination therapies, will be critical factors in determining success in this competitive landscape [4].

具体来看，CXO、创新药等概念集体下挫，晶泰控股、三生制药、微创机器人、药明合联、药明生 物、信达生物等领跌。 招商国际表示，在2025年创新药BD出海授权交易爆发式增长的基础上，2026年初已经有多个BD落地， 体现了中国创新药出海授权交易较高的景气度。 港股市场再度震荡调整，医药板块领跌，恒生生物科技指数跌超2%，聚焦创新药产业的恒生医药ETF （159892）、聚焦CXO+AI医疗的港股通医疗ETF（520510）均跌超2%。 ...

Group 1 - Since September 2024, the proportion of southbound capital transactions has rapidly increased to 20%-30%, nearly doubling compared to before 2024 [2][5] - In 2025, both active and passive foreign capital have become synchronous indicators of the Hong Kong stock market, showing no leading characteristics [2][5] - During sharp declines or corrections in the Hong Kong stock market, southbound capital tends to buy against the trend [2][5] Group 2 - Each round of pricing power competition typically begins with the optimization of the Stock Connect policy or the influx of incremental capital, which usually flows into dividend and scarce assets [5] - Net outflows of southbound capital often occur in response to adverse industry policies or external macroeconomic environments, particularly in sectors where foreign capital pricing power is increasing, such as software services, hardware equipment, consumer services, and discretionary retail [5][12] - Industries less likely to experience significant net outflows include those favored by long-term capital, such as banking, telecommunications, and public utilities, unless there are clear adverse policies affecting the sector [5][12] Group 3 - The proportion of medium to long-term capital in the current round of southbound capital inflow into Hong Kong stocks has increased, with insurance capital making 41 stakes, 35 of which are in H-shares, marking the highest record in the past decade [8] - Key industries for increased holdings include discretionary retail, finance (banking, insurance), innovative pharmaceuticals, software services, and hardware equipment [8] Group 4 - Current industries with pricing power for southbound capital and Chinese capital include semiconductors and dividend stocks, while industries lacking pricing power include internet, hardware equipment, software services, home appliances, and media [11][12] - Active management public funds have low pricing power in the Hong Kong stock market, focusing heavily on AI-related CSP giants, electronics, and innovative pharmaceuticals [16]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [5]. Core Insights - The report highlights the strong performance of WuXi AppTec and its subsidiaries, indicating robust growth momentum in the CXO sector. WuXi AppTec is expected to achieve a revenue of CNY 45.456 billion in 2025, representing a year-on-year increase of 15.84%, with TIDES business revenue projected to grow over 90% [2][21]. - The report emphasizes the recovery and structural upgrade trends in the CXO industry, driven by the resurgence of demand and the warming of investment in the innovative drug supply chain [23]. Summary by Sections Market Review - Last week, the pharmaceutical and biotechnology index fell by 0.39%, outperforming the CSI 300 index by 0.23 percentage points but underperforming the ChiNext index by 1.50 percentage points, ranking 27th among 31 sub-industries [1][16]. Company Performance - WuXi AppTec's subsidiaries reported strong earnings forecasts, with WuXi Biologics adding 209 comprehensive projects in 2025, two-thirds of which are bispecific antibodies and ADC drugs. The company aims for a compound annual growth rate of 30%-35% in revenue from 2025 to 2030 [2][22]. - The report recommends focusing on CXO chain companies such as WuXi AppTec (A+H), WuXi Biologics (H), and WuXi AppTec's subsidiaries, indicating a positive outlook for these firms [23][27]. Investment Strategy - The report suggests that future investments in the pharmaceutical sector should increasingly focus on the clinical value of drugs, driven by domestic and international policy changes. It highlights the importance of innovative drug supply chains and high-end medical devices, recommending companies like Mindray Medical and United Imaging Healthcare [3][25]. Financial Projections - Key companies are projected to show significant growth, with earnings per share (EPS) and price-to-earnings (PE) ratios indicating strong investment potential. For instance, WuXi AppTec is expected to have an EPS of CNY 5.07 in 2025, with a PE ratio of 19 [4]. Clinical Development Updates - Recent clinical developments include new applications for drugs from companies like InnoCare Pharma and Hengrui Medicine, with several drugs in various clinical trial phases [31][32]. Market Dynamics - The report notes that the pharmaceutical manufacturing industry experienced a year-on-year revenue decline of 2.0% in the first eleven months of 2025, indicating challenges in the sector [52]. Policy and Economic Environment - The report discusses the structural shift in domestic policies favoring innovative drugs and the anticipated global demand growth due to aging populations, which is expected to benefit the pharmaceutical industry [26].